Microcircuit precision medicines for cognitive disorders
Location
250 College Street, Suite 131, Toronto, Ontario M5T 1R8, Canada
Employees
1-10
Founded
2019
Funding Category
Seed
Product Features & Capabilities
DPX-101, a positive allosteric modulator targeting α5-GABA-A receptor
Other Considerations
Published preclinical proof of concept data for DPX-101; IND application clearance for Phase 1 trial of DPX-101; Focus on cognitive deficits in Alzheimer's and other brain disorders